PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast - Jonathan Corren, MD - Reducing the Burden of Chronic Rhinosinusitis With Nasal Polyps on Patient Quality of Life: An Exploration of Novel and Emerging Biologic Therapy

Jonathan Corren, MD - Reducing the Burden of Chronic Rhinosinusitis With Nasal Polyps on Patient Quality of Life: An Exploration of Novel and Emerging Biologic Therapy

01/12/21 • 30 min

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Go online to PeerView.com/XNY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps discusses novel and emerging biologic therapies to improve the quality of life for patients with chronic rhinosinusitis with nasal polyps. Upon completion of this activity, participants should be better able to: Recognize the burden that chronic rhinosinusitis with nasal polyps (CRS/NP) on patient quality of life, Describe the pathophysiology of CRS/NP and its relevance to novel therapeutic targets, Assess the latest clinical evidence regarding efficacy and safety for available and emerging treatments for CRS/NP, Apply individualized treatment plans, including the use of targeted biologic therapy, for patients with CRS/NP inadequately controlled on standard therapy.

Previous Episode

undefined - Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

Ian W. Flinn, MD, PhD / Caron Jacobson, MD / Preetesh Jain, MBBS, MD, DM, PhD -Rewriting Patient Care in Mantle Cell Lymphoma: How Innovative Therapy Is Poised to Challenge Conventional Treatment

Go online to PeerView.com/MBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent emergence and regulatory approval of multiple novel agent classes, such as Bruton’s tyrosine kinase (BTK) inhibitors and immunomodulatory drugs (IMiDs), in the management of mantle cell lymphoma (MCL) has offered clinicians and patients a greater variety of effective therapeutic options in this challenging clinical setting. At the same time, researchers continue to assess the potential of BCL-2 targeting agents and BTK inhibitor combinations, while new science has led to the regulatory approval of chimeric antigen receptor (CAR)-T cell therapy in relapsed disease. In this “Clinical Consults” activity, experts will offer guidance on key findings that have decisively turned the field away from chemotherapy-centric care. Upon completion of this activity, participants should be better able to: Summarize current recommendations for managing newly diagnosed and relapsed/refractory MCL based on factors such as treatment history, disease characteristics, or need for aggressive therapy, Discuss evidence surrounding novel treatment regimens that include BTK inhibitor, BCL-2 inhibitor, immunomodulatory, or adoptive cell therapy components across the MCL disease spectrum, Recommend therapy with novel components for the management of patients with MCL after consideration of baseline prognostic factors and/or treatment history, Manage the unique spectrum of adverse events associated with novel therapeutics in patients with MCL.

Next Episode

undefined - Steven M. Horwitz, MD - Precision Medicine in Hematologic Cancers: Lessons for Diagnostic and Treatment Protocols in CD30- and CD123-Expressing Disease

Steven M. Horwitz, MD - Precision Medicine in Hematologic Cancers: Lessons for Diagnostic and Treatment Protocols in CD30- and CD123-Expressing Disease

Go online to PeerView.com/FSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As precision medicine has taken a varying course in the setting of hematologic cancers, safely integrating effective, novel therapeutics into the management of patients whose cancers express markers such as CD30 and CD123 is more important than ever. In this activity, our experts discuss the diagnostic and treatment implications of these markers in various hematologic disease settings and use workshop-style educational segments with patient cases and clinical scenarios to illustrate the medical benefits of precision medicine for hematologic cancers defined by CD30 and CD123 expressions. Upon completion of this activity, participants should be better able to: Describe the significance of CD30 and CD123 in a range of hematologic cancers, including implications for diagnosis, immunophenotypic/molecular testing, and prognosis, Cite current efficacy and safety evidence on the use of novel therapeutics in CD30-expressing lymphoma, including in patients with newly diagnosed or relapsed disease, Discuss current evidence on the use of CD123-targeting agents in a range of hematologic cancers characterized by CD123 expression, Integrate novel therapeutics into the management of patients with newly diagnosed or relapsed/refractory Hodgkin or T-cell lymphoma, blastic plasmacytoid dendritic cell neoplasm, and chronic myelomonocytic leukemia, Manage safety considerations associated with the use of novel therapeutics in patients with CD30- or CD123-expressing malignancies.